Gene polymorphisms of TACR1 serve as the potential pharmacogenetic predictors of response to the neurokinin-1 receptor antagonist-based antiemetic regimens: a candidate-gene association study in breast cancer patients-Reference-Cited by-同舟云学术

Gene polymorphisms of TACR1 serve as the potential pharmacogenetic predictors of response to the neurokinin-1 receptor antagonist-based antiemetic regimens: a candidate-gene association study in breast cancer patients

Published:2024-04-27 Issue:2 Volume:94 Page:237-250
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Ghorbani Marziyeh,Namazi Soha,Dehghani Mehdi,Razi Farideh,Khalvati Bahman,Dehshahri Ali^ORCID

Funder

Vice-Chancellor for Research, Shiraz University of Medical Sciences

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00280-024-04661-9.pdf

Reference59 articles.

1. Aapro M (2018) CINV: still troubling patients after all these years. Support Care Cancer 26(Suppl 1):5–9. https://doi.org/10.1007/s00520-018-4131-3

2. Yeo W, Mo FKF, Yip CCH et al (2021) Quality of life associated with nausea and vomiting from anthracycline-based chemotherapy: a pooled data analysis from three prospective trials. Oncologist 26(12):e2288–e2296. https://doi.org/10.1002/onco.13978

3. Kuchuk I, Bouganim N, Beusterien K et al (2013) Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat 142(1):101–107. https://doi.org/10.1007/s10549-013-2727-3

4. Schwartzberg L, Harrow B, Lal LS et al (2015) Resource utilization for chemotherapy-induced nausea and vomiting events in patients with solid tumors treated with antiemetic regimens. Am Health Drug Benefits 8(5):273–282

5. Roeland EJ, Ruddy KJ, LeBlanc TW et al (2020) What the HEC? Clinician adherence to evidence-based antiemetic prophylaxis for highly emetogenic chemotherapy. J Natl Compr Canc Netw 18(6):676–681. https://doi.org/10.6004/jnccn.2019.7526